Despite the challenges traditionally associated with copper-67 production a number of highly successful human clinical trials have been performed with antibodies linked to copper-67 payload, demonstrating high response rates, higher tumor uptake and doses, and longer residence time in tumor than alternate radioisotopes. The targeted diseases include Non-Hodgkin Lymphoma (NHL), colon and bladder cancer.
New clinical trials are now underway.
Click on the links below to access published articles, or contact us for further information:
Iotron Medical, a spin-out business of Iotron Industries - providing innovative solutions using electron beam technology for more than 25 years
If you have any queries or wish to contact us:
For partnering opportunities:
To buy radioisotope: